GlassScriptPhysician profile
Rose M Graham
NPI 1609302868
$1,206.60
in general payments reported to CMS, 2019-2025
11 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.10 · 2022: $199 · 2023: $610 · 2024: $68.97 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954 · Education: $21.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.06 |
| Education | $21.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $707.22 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $165.04 | 2023-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.25 | 2022-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $57.67 | 2021-2024 | Breztri |
| United Therapeutics Corporation | $44.21 | 2023 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $43.86 | 2023 | Dupixent |
| Paratek Pharmaceuticals, INC. | $34.79 | 2023 | Nuzyra |
| Verona Pharma, INC. | $29.63 | 2025 | Ohtuvayre |
| Baxter Healthcare | $24.69 | 2022 | |
| Mylan Specialty L.P. | $20.93 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $16.31 | 2023 | Recarbrio, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.